PENTIXAPHARM HOLDING N AG (PTP) - Total Assets
Based on the latest financial reports, PENTIXAPHARM HOLDING N AG (PTP) holds total assets worth €38.51 Million EUR (≈ $45.02 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PENTIXAPHARM HOLDING N AG - Total Assets Trend (2021–2025)
This chart illustrates how PENTIXAPHARM HOLDING N AG's total assets have evolved over time, based on quarterly financial data. Also see PTP market cap overview for the company's overall valuation and market capitalisation.
PENTIXAPHARM HOLDING N AG - Asset Composition Analysis
Current Asset Composition (December 2025)
PENTIXAPHARM HOLDING N AG's total assets of €38.51 Million consist of 14.3% current assets and 85.7% non-current assets. Review total liabilities of PENTIXAPHARM HOLDING N AG to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 11.1% |
| Accounts Receivable | €31.00K | 0.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €32.28 Million | 77.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how PENTIXAPHARM HOLDING N AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See PENTIXAPHARM HOLDING N AG stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PENTIXAPHARM HOLDING N AG's current assets represent 14.3% of total assets in 2025, an increase from 8.8% in 2021.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2025, up from 8.2% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 77.0% of total assets, a decrease from 85.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 77.1% of total assets.
PENTIXAPHARM HOLDING N AG Competitors by Total Assets
Key competitors of PENTIXAPHARM HOLDING N AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
PENTIXAPHARM HOLDING N AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.55 | 2.56 | 1.95 |
| Quick Ratio | 1.55 | 2.56 | 1.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.65 Million | €9.90 Million | €6.39 Million |
PENTIXAPHARM HOLDING N AG - Advanced Valuation Insights
This section examines the relationship between PENTIXAPHARM HOLDING N AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.03 |
| Latest Market Cap to Assets Ratio | 1.12 |
| Asset Growth Rate (YoY) | -37.9% |
| Total Assets | €41.86 Million |
| Market Capitalization | $46.89 Million USD |
Valuation Analysis
Above Book Valuation: The market values PENTIXAPHARM HOLDING N AG's assets above their book value (1.12x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: PENTIXAPHARM HOLDING N AG's assets decreased by 37.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PENTIXAPHARM HOLDING N AG (2021–2025)
The table below shows the annual total assets of PENTIXAPHARM HOLDING N AG from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €41.86 Million ≈ $48.94 Million |
-37.88% |
| 2024-12-31 | €67.39 Million ≈ $78.78 Million |
-8.19% |
| 2023-12-31 | €73.40 Million ≈ $85.81 Million |
+36.24% |
| 2022-12-31 | €53.88 Million ≈ $62.99 Million |
+84.85% |
| 2021-12-31 | €29.15 Million ≈ $34.07 Million |
-- |
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorde… Read more